FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case
#501
Introduction: The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.
Aim(s): We report the case of a 55-year-old woman treated with a modified FOLFOX7 regimen.
Materials and methods: Clinical, biological and radiological data were collected in a patient with an aggressive advanced well-differentiated neuroendocrine pancreatic tumor treated by modified FOLFOX7.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Bengrine-Lefevre L, Marijon H, Afchain P, Tournigand C, De Gramont A,
Keywords: well-differentiated endocrine tumor, FOLFOX, thrombotic microangiopathy,
To read the full abstract, please log into your ENETS Member account.